Home › Compare › AGREF vs ABBV
AGREF yields 2500.00% · ABBV yields 3.06%● Live data
📍 AGREF pulled ahead of the other in Year 1
Combined, AGREF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AGREF + ABBV for your $10,000?
Argonaut Resources NL operates as a mineral exploration and development company in Zambia and Australia. It primarily explores for iron oxide, lithium, uranium, copper, gold, cobalt, and nickel deposits. The company holds 90% interests in the Lumwana West project comprising one exploration licence; the Kamapanda project consisting of one exploration licence and covering an area of 225 square kilometers; and the Kalaba East project located in North-Western province, Zambia. It also has 80% interest in the Higginsville joint venture project covering one exploration licence located in the Eastern Goldfields of Western Australia; and holds 100% interest in the Murdie project comprising two exploration licence covering an area of 1,105 square kilometers located in Eastern Gawler Craton of South Australia. In addition, the company holds interest in the Torrens joint venture project covering one exploration licence; and the Frome project comprising three exploration licence covering an area of 2,894 square kilometers located in South Australia. Further, it holds 100% interest in the Kroombit project consisting of ML 5631 and the surrounding mineral development licence MDL 2002 located in Queensland; and the Aroona project comprising one exploration licence located in Southern Willouran Ranges, South Australia. The company was formerly known as Star Mining Corporation NL. Argonaut Resources NL was incorporated in 1985 and is based in Adelaide, Australia.
Full AGREF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.